CoChat
Sign Up
Cited by 129Blood Pressure and Hypertension StudiesChronic Kidney Disease and DiabetesRenal and Vascular Pathologies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension

Ott, Christian, Mahfoud, Felix, Schmid, Axel, Toennes, Stefan W., Ewen, Sebastian, Ditting, Tilmann, Veelken, Roland, Ukena, Christian, Uder, Michael, Böhm, Michael, Schmieder, Roland E.·2015·Journal of Hypertension
DOI 10.1097/hjh.0000000000000556
Open this paper in CoChat — free account

Abstract

OBJECTIVES: Arterial hypertension and increased sympathetic activity are underlying pathogenetic mechanisms of the progressive loss of renal function in patients with chronic kidney disease (CKD). Meta-analyses have shown that impaired renal function is an independent cardiovascular risk factor. We hypothesized that renal denervation (RDN) decreases the decline of renal function in patients with CKD stages 3 and 4 and treatment-resistant hypertension. METHODS: We performed an observational study of 27 patients with CKD stages 3 and 4, office blood pressure (BP) ≥ 140/90 mmHg, while on at least three antihypertensive drug classes including diuretic, and diagnosis confirmed by 24-h ambulatory BP measurement ≥ 130/80 mmHg. All patients underwent catheter-based RDN using the Symplicity Flex RDN System (Medtronic Inc., Santa Rosa, California, USA). Renal function was evaluated for up to 3 years prior and 1 year after RDN. The change in estimated glomerular filtration rate (eGFR) was calculated by regression slope individually for each patient before and after RDN. The study was registered at http://www.clinicaltrials.gov (ID: NCT01442883). RESULTS: Mean baseline BP was 156 ± 12/82 ± 13 mmHg, despite treatment with 6.2 ± 1.1 antihypertensive drugs. One year after RDN, office BP was reduced by 20 ± 20 (P < 0.001)/8 ± 14 mmHg (P = 0.005) and average 24-h ambulatory BP by 9 ± 14 (P = 0.009)/4 ± 7 mmHg (P = 0.019). Before RDN, eGFR declined by -4.8 ± 3.8 ml/min per 1.73 m per year, and after RDN eGFR improved by +1.5 ± 10 ml/min per 1.73 m at 12 months (P = 0.009). CONCLUSIONS: Our observational pilot study in patients with CKD stages 3 and 4 indicates that treatment of hypertension with RDN decreases BP and slows or even halts the decline of renal function.

Overview

Integrity signals

Registry

Crossref · 10.1097/hjh.0000000000000556

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 129

Related

See all

Metadata

Authors
Ott, C., Mahfoud, F., Schmid, A., Toennes, S. W., Ewen, S., Ditting, T., Veelken, R., Ukena, C., Uder, M., Böhm, M., & Schmieder, R. E.
Affiliations
  • Goethe University Frankfurt (DE)
  • Universitätsklinikum des Saarlandes (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Corresponding author
Schmieder, Roland E.
ORCID
Venue
Journal of Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2015-06
Volume
33
Issue
6
Pages
1261-1266
ISSN
0263-6352 (ISSN-L)
DOI
10.1097/hjh.0000000000000556
OpenAlex
W2088323626
Cited by
129
References
34
Citations by year
2026: 12 · 2025: 6 · 2024: 7 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 11 · 2019: 8 · 2018: 7 · 2017: 17 · 2016: 11 · 2015: 11
FWCI
11.15
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Funders
European Renal Association-European Dialysis and Transplant Association
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
Keywords
renal denervation, chronic kidney disease, resistant hypertension, renal function, estimated glomerular filtration rate, blood pressure reduction, sympathetic nervous system, catheter ablation, ambulatory blood pressure, estimated glomerular filtration rate decline
MeSH terms
Aged, Antihypertensive Agents, Blood Pressure, Blood Pressure Determination, California, Cardiovascular Diseases, Diuretics, Female, Glomerular Filtration Rate, Humans, Hypertension, Kidney, Male, Middle Aged, Pilot Projects, Risk Factors, Sympathectomy, Sympatholytics, Treatment Outcome, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review